SCHEMBL2299079

SCHEMBL2299079

O=C(O)COc1ccc(OCc2ccc(-c3ccccc3)nc2N2CCCCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACA Q13085 1/20 0.45
LMNA P02545 4/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TRPV1 Q8NER1 1/20 0.44
HPGD P15428 1/20 0.44
HIF1A Q16665 1/20 0.44
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
FFAR4 Q5NUL3 1/20 0.43
POLB P06746 1/20 0.42
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.40
ACHE P22303 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299993 0.77 FFAR4 (0.52) ACACAMEN1KMT2APPARGPPARD
SCHEMBL2300943 0.76 ALDH1A1 (0.50) ACACALMNAMEN1KMT2AALDH1A1
SCHEMBL12427068 0.76 TRPV1 (0.48) LMNAALDH1A1SMN1; SMN2TRPV1HPGD
SCHEMBL2300159 0.74 FFAR4 (0.48) ACACAMEN1KMT2AALDH1A1HPGD
SCHEMBL14931854 0.73 FFAR4 (0.47) ACACALMNAMEN1KMT2AALDH1A1
SCHEMBL2300444 0.71 PLA2G4B (0.50) ACACAPPARGPPARDFFAR4TSHR
SCHEMBL14931887 0.71 ALDH1A1 (0.53) LMNAALDH1A1SMN1; SMN2TRPV1HPGD
Hydrochloric Acid SCHEMBL11826017 0.69 ITGB3 (0.63) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6238462 0.68 FFAR1 (0.70) PPARGPPARDFFAR4ALOX15
SCHEMBL422442 0.66 ALOX15 (0.76) ACACALMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US claimed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP claimed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US claimed
WO-2016149299-A1 THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION EPINOVA THERAPEUTICS CORP. (US) 2016-09-22 WO disclosed
US-20160271149-A1 THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION EPINOVA THERAPEUTICS CORP. 2016-09-22 US disclosed
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US disclosed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP disclosed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES PPARD, PPARA, PPARG ACACA 147/4885LMNA 1140/4885MEN1 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.